Results 141 to 150 of about 1,552,194 (255)

Intratendinous Porcine‐Derived Type I Collagen Injections Result in Clinical and Radiographic Improvement of Rotator Cuff Tendinopathy 1 Year After Treatment

Arthroscopy, Sports Medicine, and Rehabilitation, EarlyView.
Purpose To evaluate the clinical and radiological effectiveness of porcine‐derived type I collagen injections in patients with symptomatic rotator cuff tendinopathy. Methods In this monocentric pilot study conducted between 2022 and 2025, adults with clinically and radiologically confirmed rotator cuff tendinopathy received 3 ultrasound‐guided ...
Pietro Simone Randelli, Antonio Muzio, Carlo Stoppani, Chiara Fossati, Mauro Battista Gallazzi, Alessandra Menon   +5 more
wiley   +1 more source

CD14 Plays a Critical Role in Pain and Inflammation Across Multiple Models of Post‐traumatic Osteoarthritis

Arthritis &Rheumatology, EarlyView.
Objective We employed global genetic deletion of CD14 and intra‐articular CD14 blockade across multiple murine osteoarthritis (OA) models that vary in severity of pathology and rate of progression to test the hypothesis that CD14 inhibition attenuates synovial inflammation and associated pain during disease progression.
Kevin G. Burt, Sanique M. South, Natalie S. Adamczyk, Vu Nguyen, Shingo Ishihara, Cheng Zhou, Kate L. Sharp, Sung Y. Kim, Anna E. Rapp, Baofeng Hu, Lance A. Murphy, Li‐Yin Hung, De'Broski Herbert, Joshua F. Baker, Robert L. Mauck, Timothy M. Griffin, Anne‐Marie Malfait, Rachel E. Miller, Carla R. Scanzello   +18 more
wiley   +1 more source

The Role of Polydeoxyribonucleotide as a Biotherapy for Musculoskeletal Disorders. [PDF]

Int J Mol Sci
Choi J, Yoo YM.
europepmc   +1 more source

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration

Arthritis &Rheumatology, EarlyView.
Objective To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin‐6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK‐pot collaboration ...
Zubeyir Salis, Denis Mongin, Denis Choquette, Louis Coupal, Catalin Codreanu, Florenzo Iannone, Roberto Caporali, Tore K. Kvien, Sella Provan, Ruth Fritsch‐Stork, Dan Nordström, Nina Trokovic, Karel Pavelka, Jakub Závada, Ana Rodrigues, Ziga Rotar, Prodromos Sidiropoulos, Irini Flouri, Céline Lamacchia, Michele Iudici, Delphine Courvoisier, Kim Lauper, Axel Finckh   +22 more
wiley   +1 more source

Editorial: Rehabilitation strategies for musculoskeletal disorders. [PDF]

Front Rehabil Sci
Alito A, Portaro S.
europepmc   +1 more source

Nerve Growth Factor is Sufficient to Cause Multiple Osteoarthritis‐Relevant Pathologic Features in Naïve Murine Knee Joints

Arthritis &Rheumatology, EarlyView.
Objective Nerve growth factor (NGF), a key mediator of pain, is increased in osteoarthritic (OA) joints. Antibodies against NGF show analgesic effects in painful knee OA, but clinical development was stopped because of side effects in the joints. Knowledge about the biologic effects of NGF on joint tissues is limited. Therefore, we explored the effects
Alia M. Obeidat, Michael D. Newton, Jun Li, Baofeng Hu, Shingo Ishihara, Lindsey Lammlin, Lucas M. Junginger, Easton C. Farrell, Lai Wang, Frank C. Ko, Richard J. Miller, Carla R. Scanzello, Tristan Maerz, Rachel E. Miller, Anne‐Marie Malfait   +14 more
wiley   +1 more source

Ocular Clues in Musculoskeletal Disorders: A Narrative Review for Orthopaedic Specialists. [PDF]

J Am Acad Orthop Surg Glob Res Rev
Alhomaidhi S, Alrabai HM, Alsabbagh L, Addar A.   +3 more
europepmc   +1 more source

T cells, the Next Big Target in Axial Spondyloarthritis?

Arthritis &Rheumatology, EarlyView.
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by complex immune dysregulation, with T cells playing a central role in its pathogenesis. In this review, we synthesize current knowledge on diverse T cell subsets in axSpA, their pathogenic mechanisms, and emerging therapeutic strategies targeting these cells. We highlight
Mansi K. Aparnathi, Nigil Haroon
wiley   +1 more source

Musculoskeletal Disorders: From Molecular Pathology to Novel Therapeutic Approach. [PDF]

Int J Mol Sci
Lucha-López MO.
europepmc   +1 more source

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia, Wanyi Lin, Zhangyi Zhao, Fenglin Wu, Chaoyu Gu, Yuankai Sun, Zhe Ding, Chang Wei, Xinyu Li, Cuiwei Xie, Peng Xia, Zhen Xia, Xuesong Liu, Shaoying Yang, Chunyan Zhang, Hanlin Yin, Liangjing Lu   +16 more
wiley   +1 more source